“…Since many CA isoforms are involved in diverse physio/pathological conditions such as glaucoma (hCA I, II, IV and XII), edema (hCA II, IV, XIV as the most important), central nervous system (CNS)-related pathologies (hCAVII and XIV are particularly involved in the epilepsy) and tumors (hCA IX and hCA XII are strictly associated with hypoxic tumors), it is not surprising that CAIs are used in the clinic for some applications for almost 70 years [18][19][20][21][22][23][24] . Many synthetic efforts have been made for the development of specific CAIs: in the last 15 years, in addition to the classical ''tail approach'' [10][11][12][13][14][15][16][17][25][26][27][28] which is mainly applied to classical sulfonamide inhibitors and their isosters, novel CAIs scaffolds have been also identified such as the polyamines 29 , phenols [30][31][32] , dithiocarbamates [33][34][35][36] , xanthates 37 , coumarins, thiocoumarins, 2-thioxocoumarins, coumarine oximes 4,38,39 . Sulfocoumarins are the latest CAI class identified and similarly to the coumarins showed the most selective inhibition profiles against the pathologically valuable CA isoforms 1,9,[40][41][42][43][44] .…”